The latest myeloma news
Daratumumab in multiple myeloma: Reassessment shows hint of considerable added benefit
An early benefit assessment conducted by the German Institute for Quality and Efficiency in Health…
Browsing: Myeloma
ASH 2021: Bispecific antibody shows 75% response rate at highest dose levels in heavily pretreated multiple myeloma
New results for higher dose level cohorts of the investigational study REGN5458 (BCMAxCD3) bispecific antibody,…
ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma
Patients receiving the anti-CD38 monoclonal antibody isatuximab in addition to the standard three- component induction…
ASH 2021: Older adults at high risk for multiple myeloma precursor condition may benefit from screening
The first results from the largest screening study yet conducted in the United States of…
Scientists identify new types of a blood cancer and potential targeted treatments
Mount Sinai researchers in the USA have developed a new model that uses DNA and…
Cancer patients with poor antibody response to COVID-19 vaccines also lack secondary immune response, study shows
Patients with multiple myeloma often mount a poor antibody response to COVID-19 vaccines. Mount Sinai…
Blood cancer awareness month
To understand blood cancer, it is important to know it mainly affects the bone marrow,…
Half of adults can’t name a single symptom of blood cancer
A survey by the charity Blood Cancer UK has found that over half of UK…
EC approves 1st anti-BCMA CAR T therapy for multiple myeloma
Bristol Myers Squibb announced that the European Commission (EC) has granted conditional marketing authorization for…
Combination drug therapy can significantly benefit patients with newly diagnosed blood cancer
A four-drug combination therapy that includes the novel drug carfilzomib can slow the progression of…